Über diesen Podcast

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

484 Folgen · Levenswetenschappen

BiotechTV - News

Von BiotechTV

In Spotify hörenFunktioniert auch im Browser

Apple PodcastsÖffnen
Pocket CastsÖffnen
Amazon MusicÖffnen
DeezerÖffnen
OvercastÖffnen

11 weitere Apps

Player FMÖffnen
CastroÖffnen
Podcast AddictÖffnen
YouTubeÖffnen
CastboxÖffnen
Podcast RepublicÖffnen
AntennaPodÖffnen
iHeartRadioÖffnen
TuneInÖffnen
FountainÖffnen

Neueste FolgeOxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 115. Okt.12 Min.

Über diesen Podcast

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Neue Folgen

At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research14. Okt. · 20 Min.
Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more7. Okt. · 24 Min.
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress5. Okt. · 27 Min.
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease2. Okt. · 21 Min.
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung29. Sept. · 8 Min.
From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage28. Sept. · 9 Min.
From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections28. Sept. · 14 Min.
Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study21. Sept. · 10 Min.
HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs16. Sept. · 15 Min.
HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA16. Sept. · 11 Min.